LMO2 (LIM domain only 2 (rhombotin-like 1))

2007-11-01   Pieter Van Vlierberghe  , Jean-Loup Huret  

ErasmusMC\\\/Sophia Childrens Hospital, Pediatric Oncology\\\/Hematology, Rotterdam, The Netherlands (PVV); Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Identity

HGNC
LOCATION
11p13
LOCUSID
ALIAS
LMO-2,RBTN2,RBTNL1,RHOM2,TTG2
FUSION GENES

DNA/RNA

Description

LMO2 belongs to a multigene family, extremely well conserved during evolution, encoding proteins containing two cystein-rich regions referred to as LIM domains: LMO1 (11p15), LMO2 (11p13), LMO3 (12p); 6 exons.

Transcription

3 transcripts: LMO2-a and LMO2-b encode the same 158-amino-acid protein; LMO2-c encodes a 151-amino-acid protein.

Proteins

Description

Small cystein rich protein with two tandemly arranged Zinc binding LIM domain motifs: named Lom2; 158 amino acids; 18 kDa; 48 % amino-acid identity with LMO1 protein.
LMO2 contains two transcription activating domains (one in N-term, in a prolin-rich 19 amino acid region, one in C-term) and two LIM domains as transcription repressing domains, selectively inhibiting the N-term activation domain (no effect on the C-term domain).

Expression

Early expressed during development, in all tissues (roughly consistent level in central nervous system, low level in thymus).
Strongly expressed in the precursors of mixed erythrocyte/macrophage/mast, erythrocyte, megakaryocyte, neutrophil and macrophage colonies, undetectable in the mature progeny.
Expressed in early B-cells, in leukemias of both the myeloid and lymphoid lineages.
Nuclear marker in normal germinal center B-cells. Also expressed in endothelial cells. High expression in the brain; expressed in the hippocampus during development.

Localisation

Nuclear.

Function

  • Hematopoiesis: LMO2 directly interacts with the basic-loop-helix protein TAL1/SCL and the GATA DNA protein GATA1. They form a transcriptional complex: LMO2 has no direct evidence in DNA binding capacity but could act as a bridging molecule bringing together different DNA binding factors (TAL1, LDB1, E12/E47, GATA1) that are essential for hematopoiesis (e.g. in the erythroid complex). This interaction is critical for the regulation of red blood cell development in early stages of hematopoiesis. TAL1 interacts specifically with the LIM domains of LMO2, which in turn binds LDB1. Because LMO2 can also bind to GATA2, a complex LMO2-GATA2 might occur at earlier stages of hematopoiesis when Gata1 is not expressed. Lmo2 has a central role in adult hematopoietic pathway regulation, on bone marrow pluripotential precursor stem cell mainly. LMO2 and TAL1 are able to partially suppress myeloid differentiation. LMO2 also interacts with retinoblastoma-binding protein 2 and elf-2 (ets transcription factor).
  • LMO2-c expression is regulated by GATA1 and PU.1; LMO2-c acts as an antagonist of LMO2-a/b, therefore blocking the transactivation of LMO2-a/b.
  • In the brain, hBEX2, LMO2, NSCL2 and LDB1 could form a similar complex.
  • Implicated in

    Disease
    Childhood T-cell ALL ; found in 5-10% of T-cell ALL.
    Cytogenetics
    A variant translocation t(7;11)(q35;p13) has been described.
    Fusion protein
    It was previously believed that LMO2 is activated after chromosomal translocation by association either the T-cell receptor a / T-cell receptor d (14q11) or T-cell receptor b gene (7q35). Chromosome breakpoints occur 25 kb upstream LMO2 gene, in a presumed transcriptional start site, inducing truncation of the promoter/control region and leading to inappropriate Lmo2 level especially in T-cells (abnormal T-cell differentiation). However, it becomes now very likely that removal of a negative regulatory element from the LMO2 locus, rather than juxtaposition to the TCRD enhancer, is the main determinant for LMO2 activation in the majority of t(11;14)(p13;q11) translocations.
    Entity name
    del(11)(p12p13) T-cell leukaemia
    Disease
    Childhood T-cell ALL; found in about 5% of T-cell ALL.
    Cytogenetics
    Cryptic deletion that varies in size.
    Fusion protein
    LMO2 is activated through a cryptic intrachromosomal deletion, del(11)(p12p13), in which a negative regulatory element (NRE), situated upstream of the LMO2 gene, is deleted. Removal of this NRE causes activation of the proximal promoter of the LMO2 gene leading to its ectopic expression.
    Entity name
    Germinal center B-cell lymphomas
    Disease
    Diffuse large-B-cell lymphomas, follicular lymphomas, Burkitt lymphomas, less often in other haematological malignancies.
    Prognosis
    LMO2 expression, together with BCL6, FN1, CCND2, SCYA3, and BCL2 expressions, is a predictor of outcome in diffuse large-B-cell lymphoma.
    Entity name
    Prostate cancer
    Note
    Expression of LMO2 is higher in prostate tumours samples than in the normal epithelium. Moreover, overexpression of LMO2 is significantly associated with advanced tumour stage, as well as with the development of distant metastasis.
    Oncogenesis
    LMO2 may play an important role in prostate cancer progression, possibly via repression of E-cadherin expression.

    Article Bibliography

    Pubmed IDLast YearTitleAuthors

    Other Information

    Locus ID:

    NCBI: 4005
    MIM: 180385
    HGNC: 6642
    Ensembl: ENSG00000135363

    Variants:

    dbSNP: 4005
    ClinVar: 4005
    TCGA: ENSG00000135363
    COSMIC: LMO2

    RNA/Proteins

    Gene IDTranscript IDUniprot
    ENSG00000135363ENST00000257818P25791
    ENSG00000135363ENST00000395833P25791
    ENSG00000135363ENST00000411482P25791

    Expression (GTEx)

    0
    5
    10
    15
    20
    25
    30
    35
    40
    45

    Pathways

    PathwaySourceExternal ID
    Transcriptional misregulation in cancerKEGGko05202
    Transcriptional misregulation in cancerKEGGhsa05202

    Protein levels (Protein atlas)

    Not detected
    Low
    Medium
    High

    References

    Pubmed IDYearTitleCitations
    382453452024Simulated microgravity altered the gene expression profiles and inhibited the proliferation of Kupffer cells in the early phase by downregulating LMO2 and EZH2.0
    382453452024Simulated microgravity altered the gene expression profiles and inhibited the proliferation of Kupffer cells in the early phase by downregulating LMO2 and EZH2.0
    359990962023Potential link of single nucleotide polymorphisms within LMO2 to the risk of cervical squamous-cell carcinoma in Chinese populations.0
    375191102023Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.0
    375734052023LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.0
    359990962023Potential link of single nucleotide polymorphisms within LMO2 to the risk of cervical squamous-cell carcinoma in Chinese populations.0
    375191102023Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.0
    375734052023LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.0
    350946912022Identification of LMO2 as a new marker for acinic cell carcinoma of salivary gland.0
    352868692022LMO2 plays differential roles in trophoblast subtypes and is associated with preeclampsia.0
    353221922022LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.6
    369052682022PAK5 is a potential target in myelodysplastic syndrome through interacting with LMO2 and GATA1.0
    350946912022Identification of LMO2 as a new marker for acinic cell carcinoma of salivary gland.0
    352868692022LMO2 plays differential roles in trophoblast subtypes and is associated with preeclampsia.0
    353221922022LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.6

    Citation

    Pieter Van Vlierberghe ; Jean-Loup Huret

    LMO2 (LIM domain only 2 (rhombotin-like 1))

    Atlas Genet Cytogenet Oncol Haematol. 2007-11-01

    Online version: http://atlasgeneticsoncology.org/gene/34/js/lib/meetings/deep-insight-explorer/

    Historical Card

    1998-06-01 LMO2 (LIM domain only 2 (rhombotin-like 1)) by  Chrysthèle Bilhou-Nabera 

    Cytogénétique,Laboratoire dHématologie-Pr RAPHAEL, Pav BROCA - 4öme étage, 78 rue du Général Leclerc, 94275 LE KREMLIN-BICETRE, France